Searched for
LUPIN PART 3
Stocks in news: IndiGo, Sammaan Capital, Bharti Airtel, GRSE, CoforgeMarkets experienced a sharp sell-off on Monday's monthly expiry day, with the Nifty closing near 22,331. Key companies like IndiGo, Bharti ...- Lupin shares gain 3%, up for second straight session. Here’s whyLupin shares saw an uptick after Jefferies raised its target price and reiterated a “Buy” rating post-strong Q2 results. The US business hi...
- Lupin season 4 release date on Netflix: Is Lupin part 4 happening?Lupin season 4 will be releasing on Netflix even though the production for the same is yet to commence, according to a report.
- Lupin shares drop 3% after Q3 resultsShares of Lupin Ltd dropped 2.8% despite a significant Q3 profit increase of 38.8% year-on-year. The company's revenue surged 102.7%, reach...
- Lupin to acquire French firm Medisol for around Rs 160 crPharmaceuticals firm Lupin Ltd on Friday said it will fully acquire French pharmaceutical company Medisol for 18 million euros (over Rs 160...
- ‘Lupin’ Part 3: When can it premiere on Netflix? Here’s what we knowNetflix Germany posted on Twitter that they had intended to reveal the release date for Lupine Part 3, but it seems someone else had other ...
- Lupin shares drop 0.3% as Sensex fallsA total of 36,555 shares changed hands on the counter till 01:28PM (IST)
- Buy Lupin, target price Rs 1150: Emkay GlobalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 42717.22 Crore) operating in Pharmaceuticals s...
- Lupin announces USFDA acceptance for a biosimilar applicationThe pegfilgrastim filing is the company's first biosimilar filing in the US and is a milestone in the drug maker's research and innovation ...
- Lupin looks to sell Japanese arm Kyowa for $600 millionKyowa grew a modest 5% over the year-ago level. Its net profit halved to Rs 68.6 crore constituting 11.3% of Lupin’s consolidated profit. "...
- Lupin's JV completes global trials for RA biosimilarThe randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.
- Who moved my market on ThursdayIn this space, ETMarkets.com tracks the elite 30 from the Sensex pack and 50 from the nimble Nifty LIVE to help you understand why the mark...
- Lupin eyes UK pharma company Sinclair for $500 millionThe skin-focused pharma company, owned by a group of private equity investors, has asked investment bank NM Rothschild to help find a buyer...
- Lupin on buying spree; to acquire German company Temmler Pharma's product portfolioA day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...
- Day 1 on Sensex: Lupin erases early gains on profit-bookingAfter rising 1.91 % to Rs 1,851.15 in intra-day trade, shares of Lupin succumbed to profit-booking and finally ended at Rs 1,811.10.
- Lupin acquires Brazilian drug firm MedquimicaThe company has acquired 100 per cent equity stake in Medquimica Industria Farmaceutica subject to certain closing conditions.
- Lupin inks pact with Merck Serono to expand in emerging marketsSales in the emerging market regions are one of the key growth drivers for Darmstadt-based Merck Serono, amounting to close to 1.8 billion ...
- Lupin forms Joint Venture with Japan's Yoshindo IncLupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...
- GeNext to prescribe new growth formula for LupinDesh Bandhu Gupta built Lupin into a $1-billion enterprise, but he will chart the journey to $3 billion and beyond with his two children.
- Lupin to launch more branded generics in USLupin Pharma will launch a new branded generic drug in the US every year for specialised therapeutic areas.
Load More
